Pharmacokinetics of Oral D-Serine in D-Amino Acid Oxidase Knockout Mice

Rana Rais, Ajit G. Thomas, Krystyna Wozniak, Ying Wu, Hanna Jaaro-Peled, Akira Sawa, Christine A. Strick, Sandra J. Engle, Nicholas J. Brandon, Camilo Rojas, Barbara S. Slusher, and Takashi Tsukamoto

Department of Neurology (R.R., B.S.S., T.T.), Brain Science Institute (A.G.T., K.W., Y.W., C.R.), and Department of Psychiatry and Behavioral Sciences (H.J.-P., A.S.), Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of Neuroscience (C.A.S., N.J.B.) and Pharmacokinetics, Dynamics and Metabolism (S.J.E.), Pfizer, Groton, Connecticut

Received April 30, 2012; accepted July 26, 2012

ABSTRACT:

D-Amino acid oxidase (DAAO) catalyzes the oxidative deamination of D-amino acids including D-serine, a full agonist at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor. To evaluate the significance of DAAO-mediated metabolism in the pharmacokinetics of oral D-serine, plasma D-serine levels were measured in both wild-type mice and transgenic mice lacking DAAO. Although D-serine levels were rapidly diminished in wild-type mice ($t_{1/2} = 1.2$ h), sustained drug levels over the course of 4 h ($t_{1/2} > 10$ h) were observed in mice lacking DAAO. Coadministration of D-serine with 6-chlorobenzo[d]isoxazol-3-ol (CBIO), a small-molecule DAAO inhibitor, in wild-type mice resulted in the enhancement of plasma D-serine levels, although CBIO seems to have only temporary effects on the plasma D-serine levels due to glucuronidation of the key hydroxyl group. These findings highlight the predominant role of DAAO in the clearance of D-serine from the systemic circulation. Thus, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma D-serine levels over a sustained period of time and might have therapeutic implications for the treatment of schizophrenia.

Introduction

Cumulative evidence suggests that allosteric activation of NMDA receptors via the glycine modulatory site might have therapeutic implications for the treatment of schizophrenia (Labrie and Roder, 2010). Both glycine and D-serine, two known endogenous glycine modulatory site agonists, have been shown to ameliorate persistent negative and cognitive symptoms of the disorder (Javitt, 2010), whereas existing antipsychotic medications have failed to provide significant efficacy. D-Serine is particularly promising, because 1) the glycine modulatory site of the NMDA receptors (Matsui et al., 1995); and 3) there is no known signal transduction site modulated by D-serine other than the glycine modulatory site, which minimizes the risk of off-target toxicity.

However, clinical development of D-serine could be hampered by the high doses (120 mg/kg) required for the optimal treatment of schizophrenia (Kantrowitz et al., 2010). Furthermore, high doses of D-serine have been reported to cause selective necrosis to the pars recta region of the renal proximal tubules in the rat (Ganote et al., 1974). Moreover, one patient who received high doses (120 mg/kg) of D-serine in an open-label clinical trial showed a nephrotoxic-like pattern (Kantrowitz et al., 2010). Results of studies that used a D-amino acid oxidase (DAAO) inhibitor (Williams and Lock, 2005) and of rats lacking DAAO activity (Maekawa et al., 2005) suggest that the mechanism of D-serine-induced nephrotoxicity is associated with oxidative stress caused by hydrogen peroxide, a by-product of DAAO-mediated metabolism of D-serine in the kidneys (Fig. 1). DAAO (EC 1.4.3.3) is a flavoenzyme that catalyzes the oxidative deamination of D-amino acids, including D-serine, and produces the corresponding α-keto acids, ammonia, and hydrogen peroxide (Dixon and Kleppe, 1965a,b).

In mammals, DAAO is present in the kidneys, liver, and brain. It is interesting to note that two recent independent studies revealed that DAAO expression and activity are elevated in schizophrenia (Burnet et al., 2008; Madeira et al., 2008). Because the highest DAAO activity is found in the kidneys (Curti et al., 1992), a
substantial amount of orally administered D-serine is metabolized there. This contributes to the rapid clearance of D-serine and, consequently, the high dose required for efficacy. These findings suggest that inhibition of DAAO would exert dual beneficial effects on D-serine therapy by 1) enhancement of D-serine exposure and 2) suppression of hydrogen peroxide generation in the kidneys. Thus, DAAO inhibitors might address the issues associated with clinical use of D-serine and salvage the most clinically efficacious glycine modulatory site agonist, 6-Chlorobenz[d]isoxazol-3-ol (CBIO) is a potent competitive inhibitor of DAAO and has a $K_i$ value of 100 nM for porcine DAAO (Ferraris et al., 2008). Although its toxicity profile has not been fully established, CBIO has been tested in both mice and rats as treatment for pain and has resulted in no apparent toxicity (Gong et al., 2011; Lu et al., 2012). In another study, oral coadministration of CBIO with D-serine enhanced oral bioavailability of D-serine and its levels in the prefrontal cortex (Ferraris et al., 2008). Subsequent studies revealed that oral coadministration of CBIO with D-serine in a preclinical model of schizophrenia normalized prepulse inhibition deficits induced by (5S,10R)-(−)-5,10-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK801) at all prepulse intensities to a degree similar to that of 10-fold higher doses of D-serine alone (Hashimoto et al., 2009).

Little is understood, however, as to what extent DAAO-mediated metabolism is involved in the overall clearance of D-serine in vivo. Such information should provide insights into the extent of the benefits provided by DAAO inhibitors as pharmacoenhancers for orally dosed D-serine. In the present study, we compared plasma D-serine levels in mice with or without DAAO activity after oral administration of D-serine. The primary objective of this study was to identify, if any, other D-serine clearance pathways and assess the degree of pharmacoenhancement achieved by DAAO inhibition on oral D-serine pharmacokinetics. In addition, the ability of CBIO to enhance D-serine pharmacokinetics was evaluated in the light of its in vitro metabolic stability in plasma and liver microsomes.

### Materials and Methods

#### Chemicals

CBIO was obtained from Maybridge (Comwall, UK). Boric acid, O-phthalaldehyde (OPA), sodium acetate, and all amino acids except D-serine and D-alanine were obtained from Sigma-Aldrich (St. Louis, MO). D-Serine and D-alanine were obtained from Bachem Bioscience (King of Prussia, PA). Liver microsomes from mice and humans, the NADPH-regenerating system, and UGT Reaction Mix were purchased from BD Biosciences (San Jose, CA). All solvents [high-performance liquid chromatography (HPLC) grade] and N-tet-butyloxycarbonyl-L-cysteine (Boc-L-Cys) were purchased from EMD Biosciences (San Diego, CA) and Novabiochem (a subsidiary of EMD Biosciences; Laufelfingen, Switzerland), respectively. Glacial acetic acid, sodium hydroxide, and ultrapure water were procured from Mallinkrodt Baker, Inc. (Phillipsburg, NJ).

#### Animals

All mice were maintained in accordance with Institutional Animal Care and Use Committee regulations at the Johns Hopkins University School of Medicine. To generate the DAOn-targeting vector, recombining (Liu et al., 2003) was used to replace 1957 base pairs encompassing exons 7 and 8 of Ddop (ENSMUSTG000000042996) with a neomycin phosphotransferase cassette in a C57BL/6 bacterial artificial chromosome (IBAC) RP23-450E21; Invitrogen, Carlsbad, CA). The deletion removes the glycine that is mutated in the naturally occurring DAAO-deficient (ddY) mice and the tyrosine that is thought to be catalytically important. Splicing of exon 6 to exon 9 results in a naturally occurring D-serine therapy by increasing D-serine bioavailability and minimizing the formation of hydrogen peroxide, a potential cause of nephrotoxicity.

**Fig. 1.** DAAO-mediated metabolism of D-serine. Small-molecule DAAO inhibitors such as CBIO have the potential to provide a significant improvement to D-serine therapy by increasing D-serine bioavailability and minimizing the formation of hydrogen peroxide, a potential cause of nephrotoxicity.
using 0.4 M boric acid pH-adjusted to 9.0 with sodium hydroxide. On the day of the analysis, 10 mg each of OPA and Boc-L-Cys were dissolved in 1 ml of methanol and 3.5 ml of borate buffer added to the Boc-L-Cys-OPA mixture (derivatization reagent). A 45-μl volume of derivatization reagent was then added to a vial containing 5 μl of either the AA standard or the sample. After 2 min of derivatization at room temperature, an aliquot (10 μl) of the derivatized material was introduced into the HPLC system described below.

The HPLC system consisted of a degasser (DGU-14A; Shimadzu, Columbia, MD), pumps (LC-10ADVP; Shimadzu), an autoinjector (SIL-10ADVP; Shimadzu, Columbia, MD), and a fluorescence detector (RF-10AXL; Shimadzu). Mobile phase A was made up of 0.1 M sodium acetate buffer (pH 6.0), acetonitrile, and tetrahydrofuran [50:47:3 (v/v/v)]. Mobile phase B was made up of 0.1 M sodium acetate buffer (pH 6.0), acetonitrile, and tetrahydrofuran [50:47:3 (v/v/v)]. Amino acids were resolved by using a C18 Nova-Pak analytical column (3.9 × 300 mm, 4 μm; Waters, Milford, MA) maintained at 30°C, with a linear gradient from mobile phase A to B in 120 min, and operated at a constant flow rate of 0.8 ml/min. Fluorescence detection was carried out at 443 nm with excitation at 344 nm. Data were processed by using a system controller from Shimadzu (SCL-10A VP).

Pharmacokinetics Analysis. Plasma concentrations of d-serine were analyzed by using noncompartmental methods as implemented in the computer software program WinNonlin version 5.2 (Pharsight, Mountain View, CA). The maximum plasma concentration (C\text{max}) and time to C\text{max} (T\text{max}) were the observed values. The half-life (t\text{1/2}) was calculated as 0.693 divided by λ\text{z} (the elimination rate constant) using a uniform weighting. The area under the plasma concentration time curve (AUC) was calculated to the last quantifiable concentration. Acceptance criteria for the model were percentage of the mean concentration at each time point. To determine whether there was a significant difference between exposure as expressed by AUCs of d-serine in three cohorts (i.e., wild type, wild type with DAAO inhibitor, and the DAAO-KO), a pairwise comparison was performed by using a Z test (Yuan, 1993). The a priori level of significance was P < 0.05.

Metabolic Stability of CBIO in Plasma and Liver Microsomes. The metabolic stability of CBIO was evaluated by using mouse and human plasma and liver microsomes. For plasma stability, a 5 μM compound was spiked in plasma, and the reaction (150 μl) was stopped at 0, 15, 30, and 60 min by the addition of acetonitrile (300 μl) spiked with internal standard ([IS] 0.1 mM phenyl acetic acid).

Phase I and phase II metabolic stability assays for CBIO were conducted in mouse and human liver microsomes. For phase I metabolism, the reaction was carried out with 100 mM potassium phosphate buffer (pH 7.4) in the presence of an NADPH-regenerating system (1.3 mM NADPH/3.3 mM glucose 6-phosphate/3.3 mM MgCl\text{2}/0.4 U/ml glucose-6-phosphate dehydrogenase/50 μM sodium citrate). Reactions in triplicate were initiated by addition of the liver microsomes (mouse or human) to the incubation mixture (compound final concentration was 10 μM; 0.5 mg/ml microsomes). For the phase II glucoronidation reaction, CBIO was added to Tris-HCl buffer [50 mM (pH 7.5)] with microsomes (0.5 mg/ml), along with MgCl\text{2} (8 mM), and alanethicin (25 μg/ml) and preincubated at 37°C. The reaction was initiated (in triplicate) with uridine 5’-diphospho-glucuronic acid (UDPGA) at a final concentration of 2 mM. Control experiments in the absence of NADPH and UDPGA were carried out for both phase I and phase II metabolism, respectively, to determine the specific cofactor-free degradation. At predetermined times (0, 15, 30, and 60 min), aliquots of the mixture were removed and the reaction quenched by the addition of two times the volume of ice-cold acetonitrile spiked with the IS. Compound disappearance was monitored over time by using a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method.

Separation of the analyte from potentially interfering material was achieved by using a Waters X-Terra (50 × 2.1 mm i.d.) column packed with a 3.5-μm C18 stationary phase protected by a guard column packed with 3.5-μm RP18 material. The mobile phase used was composed of acetonitrile/water [70:30 (v/v)] containing 0.1% formic acid delivered isocratically at a flow rate of 0.2 ml/min for a total run time of 5 min. The retention time for CBIO and the IS was 1.2 ± 0.3 min. The column effluent was monitored by using a Waters HPLC, in the negative-ionization mode. The spectrometer was programmed to allow the [M-1] mass transitions of CBIO at an m/z of 168 > 132 and an m/z of 135 > 90.8 for the IS.

Results

Plasma Pharmacokinetics of d-Serine in Wild-Type and DAAO Knockout Mice. d-Serine concentration-time profiles in plasma after oral administration of d-serine are shown in Fig. 2, and the pharmacokinetic parameters are summarized in Table 1. The basal plasma levels of d-serine were 3.5 and 10.8 μM in wild-type and DAAO KO mice, respectively. Similar d-serine levels were reported for serum samples from ddY mice with and without DAAO activity (Morikawa et al., 2001). d-Serine was absorbed rapidly in wild-type mice after oral administration (T\text{max} within 0.7 ± 0.3 h). When d-serine was given in conjunction with CBIO, a potent DAAO inhibitor, the T\text{max}...
shifted to 1.0 h, and the C\text{max} and AUC were increased. In DAAO-KO mice, the T\text{max} was further delayed to 2.7 ± 0.9 h, and additional increases were observed in the C\text{max} and AUC values. The terminal half-lives of \( \alpha \)-serine in wild-type mice (without or with CBIO) were 1.2 ± 0.1 h and approximately 1.5 h, respectively. In contrast, DAAO-KO mice exhibited the highest C\text{max} value among the three treatment groups, and there was little sign of \( \alpha \)-serine elimination during the period of the measurement (up to 4.0 h). The half-life of \( \alpha \)-serine could not be estimated accurately because of insufficient data available for the DAAO-knockout mice and a lack of terminal elimination phase (Fig. 2).

Systemic exposure of \( \alpha \)-serine in the three cohorts was evaluated by using the AUC\text{last} values. The highest plasma exposure to \( \alpha \)-serine was achieved in DAAO-KO mice, with an AUC\text{0–last} value of 95,768 ± 6234 h \cdot ng/ml, followed by wild-type mice administered \( \alpha \)-serine and CBIO (65,778 ± 6602 h \cdot ng/ml) and wild-type mice treated with \( \alpha \)-serine alone (40,648 ± 6602 h \cdot ng/ml) without CBIO. The DAAO-KO mice had approximately 2.4-fold higher exposures compared with those of the wild-type mice and 1.4-fold higher exposures compared with those of the wild-type mice treated with CBIO, all of which were statistically significant differences (\( P < 0.05 \)). In addition, wild-type mice administered \( \alpha \)-serine with CBIO exhibited 1.6-fold higher systemic exposures compared with those of the wild-type mice treated with \( \alpha \)-serine alone (\( P < 0.05 \)). The AUC extrapolated from the AUC\text{last} was greater than 25% for DAAO-KO mice; hence, the AUC\text{0–last} value is not reported.

**In Vitro Metabolic Stability of CBIO.** In mouse and human plasma, CBIO was found to be stable over a period of 60 min (data not shown). In mouse and human liver microsomal incubations in the presence or absence of NADPH (Fig. 3), no metabolism of CBIO was observed (\(~100\%\) remaining at the end of a 60-min incubation), which indicates that CBIO is not a substrate of cytochrome P450 enzymes. In microsomes fortified with UDPGA, however, CBIO was metabolized rapidly; 10% (mouse) and 22% (human) of the parent compound remained after 60 min of incubation (Fig. 3). Subsequently, the possible formation of CBIO-glucuronide (exact mass: 345.03 Da) was examined in the microsome mixtures (Fig. 4). A new peak with a distinct mass with an m/z of 344.02 (M-1) was detected by LC/MS analysis in both mouse and human microsomes fortified with UDPGA (data not shown).

**Brain Levels of \( \alpha \)-Serine.** Levels of \( \alpha \)-serine were measured in two regions of the brain (the cerebellum and the cortex) of wild-type and DAAO-KO mice. For the \( \alpha \)-serine-treated groups, tissues were taken 1 h after oral administration of \( \alpha \)-serine. As shown in Fig. 5A, negligible basal levels of \( \alpha \)-serine were detected in the cerebellum of wild-type mice. \( \alpha \)-Serine levels did not increase significantly in the cerebellum even in \( \alpha \)-serine-treated (no CBIO) wild-type mice 60 min after oral administration. Substantially higher basal quantities of \( \alpha \)-serine were found in the cerebellum of DAAO-KO mice (Fig. 5B). \( \alpha \)-Serine levels were even higher in DAAO-KO mice treated with \( \alpha \)-serine, although the difference was not statistically significant. In the cortex, the basal \( \alpha \)-serine levels were nearly identical between the wild-type and DAAO-KO mice. Although both the wild-type and DAAO-KO mice showed higher levels of \( \alpha \)-serine after \( \alpha \)-serine treatment, neither of them achieved statistically significant increases.

**Discussion**

In the present study, we examined the significance of DAAO-mediated metabolism (Fig. 1) in the pharmacokinetics of orally administered \( \alpha \)-serine. Plasma levels of \( \alpha \)-serine before \( \alpha \)-serine treatment were 3.5 and 10.8 \( \mu \)M in wild-type and DAAO-KO mice, respectively. Although genetic deletion of DAAO seems to result in increased plasma levels of \( \alpha \)-serine, the origin of plasma \( \alpha \)-serine is not well understood and could be attributed to diet (Friedman, 1999), the level formed in the brain by serine racemase (Ohide et al., 2011), or both. When \( \alpha \)-serine was given to wild-type 129SvEv mice, \( \alpha \)-serine was immediately absorbed and followed by rapid clearance. Co-administration of CBIO, a potent DAAO inhibitor, resulted in a

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Cohorts</th>
<th>Dose</th>
<th>( T_{\text{max}} )</th>
<th>( C_{\text{max}} )</th>
<th>( T_{\frac{1}{2}} )</th>
<th>AUC\text{last}</th>
<th>AUC\text{0–last}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>30</td>
<td>0.7 ± 0.3</td>
<td>19,609 ± 1338</td>
<td>1.2 ± 0.1</td>
<td>40,648 ± 6602</td>
<td>46,023 ± 8976</td>
</tr>
<tr>
<td>Wild type + CBIO*</td>
<td>30</td>
<td>1.0</td>
<td>24,277</td>
<td>1.5</td>
<td>&gt;10†</td>
<td>80,899</td>
</tr>
<tr>
<td>Knockout</td>
<td>30</td>
<td>2.7 ± 0.9</td>
<td>27,791 ± 2019</td>
<td>&gt;10†</td>
<td>95,768 ± 6234</td>
<td>—‡</td>
</tr>
</tbody>
</table>

* The S.D. of the data cannot be determined because of the insufficient number (2) of data points at 120 and 240 min.
† Insufficient data for accurate approximation.
‡ The AUC extrapolated from the AUC\text{max} is greater than 25%; hence, the AUC\text{0–last} value is not reported.

**FIG. 3.** Metabolic stability of CBIO in mouse (A) and human (B) liver microsomes.
than the 2-fold AUC last increase seen over the first 2 h. The much sufficient data are not available to estimate the AUC0–

dominant role in the overall plasma clearance of D-serine. Although clearance. These findings clearly indicate that DAAO plays a pre-
during the period of the measurement with little indication of plasma clearance. This explains the inability of CBIO to maintain high levels of D-serine plasma levels for a sustained period of time. As expected, CBIO had no effects on plasma levels of coadministered D-serine in DAAO-KO mice (data not shown), which confirms that the ability of CBIO to enhance plasma D-serine levels is predominantly associated with its inhibition of DAAO.

In an attempt to elucidate the mechanism by which CBIO is cleared from the circulatory system, in vitro metabolic stability was measured in plasma and liver microsomes from mice and humans. CBIO was highly stable in mouse and human plasma (>95% remaining after 2 h of incubation; data not shown). In liver microsomes from mice (Fig. 3A) and humans (Fig. 3B), no significant loss of CBIO was detected in the absence or presence of NADPH. The presence of the chloro group seems to make CBIO resistant to CYP450-mediated oxidation. In liver microsomes containing UDPGA, however, CBIO was metabolized substantially; only 10% (mouse) and 21% (human) of the parent compound remained at the end of a 60-min incubation (Fig. 3). The results clearly show that CBIO undergoes phase II glucuronidation in the liver. Because CBIO possesses only a single moiety that is possibly subject to glucuronidation (3-hydroxy group), the most likely metabolite is CBIO-3-glucuronide (Fig. 4). Indeed, we have
detected a new peak corresponding to a mass of CBIO-3-glucuronide with an increasing intensity over time in LC/MS (data not shown). Unfortunately, the 3-hydroxyl group is essential for the high-affinity binding of CBIO to the DAAO active site (Ferraris et al., 2008). Therefore, removal or masking of this functional group is expected to result in a complete loss of inhibitory potency even though it might circumvent glucuronidation. Further structural optimization of the benzof[d]isoxazol-3-ol scaffold requires careful modulation of the steric and electronic environment surrounding the hydroxyl group in a way that does not compromise the inhibitory potency while minimizing the degree of glucuronidation. It is also important to point out that glucuronidation is only one of many possible metabolic reactions that could take place at this site. Other phase II metabolic reactions, particularly methylation and sulfation, are also common at a free hydroxyl group, and much attention needs to be paid when the structural optimization of CBIO is conducted for the enhancement of metabolic stability. If such improvements do not result in prolonged plasma half-life, the possibility of metabolism by other organs needs to be explored to determine the optimal strategy for further structural optimization.

In the brain, DAAO activity is known to be highest in the cerebellum, whereas relatively low levels of DAAO activity are detected in the cortex. It is not surprising that d-serine levels in the brain are inversely correlated with DAAO activity. As shown in Fig. 5A, only negligible basal levels of d-serine were detected in the cerebellum of wild-type mice, whereas substantially higher quantities of d-serine were found in the cortex. This is consistent with the previously reported findings in other strains of mice (Morikawa et al., 2001; Labrie et al., 2009).

Oral administration of d-serine in wild-type mice did not result in increased levels of d-serine in the cerebellum 1 h after administration, presumably because of the rapid metabolism by DAAO. A slight increase in d-serine levels was observed in the cortex of d-serine-treated wild-type mice, although the difference was not statistically significant. It was previously reported that, in rats, a statistically significant increase in cortical d-serine levels was achieved only when ≥320 mg/kg doses of d-serine were given by subcutaneous injection (Smith et al., 2009). In contrast, increases of d-serine levels in cerebrospinal fluid were statistically significant at 160 mg/kg, and nearly 80-fold increases over the basal level were achieved at the highest dose tested (1280 mg/kg). These findings suggest that endogenous d-serine in the brain is mainly confined to the intracellular compartment, probably by the action of the alanine-serine-cysteine (Asc-1) transporter. Added d-serine has much less impact on its levels in homogenized brain tissues containing a substantial quantity of endogenous cytosolic d-serine. Meanwhile, extracellular d-serine concentrations such as those detected in cerebrospinal fluid are boosted more dramatically by the added d-serine as a result of the lower basal level of endogenous d-serine.

As shown in Fig. 5B, basal d-serine levels in the cerebellum of DAAO-KO mice were substantially higher than those of wild-type mice. Previous studies that used other strains of mice lacking DAAO activity also had similar results (Morikawa et al., 2001; Labrie et al., 2009). In the cortex, the basal d-serine levels were nearly identical between wild-type and DAAO-KO mice. The results are in good agreement with the negligible DAAO activity detected in the cortex of wild-type rodents (Horiike et al., 1994).

Although both the cerebellum and cortex of DAAO-KO mice had higher levels of d-serine 1 h after d-serine treatment, neither of their increases was statistically significant. We have previously shown by in vivo microdialysis in the mouse frontal cortex that oral d-serine (30 mg/kg) can increase cortical d-serine levels of wild-type ddY mice by up to 4-fold when coadministered with CBIO (Hashimoto et al., 2009). The higher relative increase seen with microdialysis indicates that the impact of added d-serine is more robust in the extracellular compartment of the brain, where the therapeutic target (NMDA receptor) for d-serine is located.

Conclusions

D-serine represents one of the most promising therapeutic agents for treating the negative symptoms and cognitive deficits of schizophrenia, which have been poorly addressed by the existing antipsychotic medications. However, d-serine therapy remains impractical for clinical application because of the high dose required for robust efficacy and the risk of nephrotoxicity. Coadministration of d-serine with a small-molecule DAAO inhibitor might address both of these issues and lead to the development of a clinically viable therapeutic approach based on d-serine. Furthermore, the pharmacoenhancing effects of DAAO inhibition could be more profound in humans, because a substantial amount of DAAO is present in human liver and first-pass metabolism of d-serine can be blocked by DAAO inhibitors. However, DAAO in the human liver might play a crucial role in metabolism and/or detoxification of endogenous/exogenous substances. Therefore, it is critical to assess the potential consequences of liver DAAO inhibition in species known to express DAAO in not only the kidney but also the liver. It is also worth noting that a cross-species comparison of urinary basal d-serine concentrations revealed that much higher levels of d-serine were found in humans compared with those of rats and mice (Huang et al., 1998; Miyoshi et al., 2009), which could be at least partially due to higher rates of renal d-serine excretion in humans. DAAO inhibitors, in theory, are incapable of minimizing the loss of d-serine by renal excretion. Hence, DAAO inhibitors might be less effective in enhancing plasma d-serine levels in humans if renal excretion plays a larger role in human d-serine pharmacokinetics.

Although CBIO has served as a useful pharmacological probe for elucidating the pharmacoenhancing effects of DAAO inhibition on d-serine (Ferraris et al., 2008; Hashimoto et al., 2009), our studies revealed that another improvement to DAAO inhibitors can be made by identifying CBIO analogs that are resistant to glucuronidation. Given the favorable oral d-serine pharmacokinetics in DAAO-knockout mice, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma d-serine levels over a sustained period of time and have therapeutic implications for the treatment of schizophrenia. In our studies, orally administered d-serine had little impact on brain tissue levels of d-serine in both wild-type and DAAO-KO mice. It is conceivable that the added d-serine contributes only a minor portion of d-serine in brain tissues and that microdialysis studies are better suited for examining central nervous system distribution of orally administered d-serine and its therapeutic effects.

Authorship Contributions

Participated in research design: Rais, Thomas, Strick, Engle, Brandon, Rojas, Slusher, and Tsukamoto.

Conducted experiments: Rais, Thomas, Wozniak, Wu, Jaaro-Peled, and Engle.

Contributed new reagents or analytic tools: Sawa.

Performed data analysis: Rais, Thomas, and Tsukamoto.

Wrote or contributed to the writing of the manuscript: Rais, Thomas, Jaaro-Peled, Sawa, and Tsukamoto.

References


**Address correspondence to:** Takashi Tsukamoto, Department of Neurology, Johns Hopkins University, 855 N. Wolfe St., Baltimore, MD 21205. E-mail: ttsukamoto@jhmi.edu